Cell Therapeutics (CTIC) rises 3% premarket.
U.K. cost gatekeeper NICE has issued a positive final draft opinion on Pixuvri.
The regulator "recommends funding the treatment as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma," the company says.
Here's CEO James Bianco: "[This] means that physicians in England and Wales now have access to the only approved therapy for their patients with aggressive B-cell NHL in the third- and fourth-line salvage setting." (PR)